{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:51Z","timestamp":1792787991559,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Heilongjiang Province Outstanding Young Teachers Basic Research Support Program","award":["YQJH2023032"],"award-info":[{"award-number":["YQJH2023032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04562-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:55:03Z","timestamp":1778475303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipid nanoparticle-mediated co-delivery of IL-33 mRNA and STING agonist modulates the breast cancer microenvironment and potentiates immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Ning","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4562_CR1","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"issue":"4","key":"4562_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"issue":"6","key":"4562_CR3","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"4562_CR4","doi-asserted-by":"publisher","first-page":"1153990","DOI":"10.3389\/fimmu.2023.1153990","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023;14:1153990.","journal-title":"Front Immunol"},{"issue":"1","key":"4562_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"key":"4562_CR6","doi-asserted-by":"publisher","unstructured":"Bullock KK, Richmond A. Beyond anti-PD-1\/PD-L1: improving immune checkpoint inhibitor responses in triple-negative breast cancer. Cancers (Basel). 2024;16(12). https:\/\/doi.org\/10.3390\/cancers16122189","DOI":"10.3390\/cancers16122189"},{"issue":"1","key":"4562_CR7","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","volume":"15","author":"AEI Hamouda","year":"2024","unstructured":"Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, Jacobs L, Bardet PMR, Knetemann E, Lefesvre P, Allonsius L, Gontsarik M, Varela I, Crabb\u00e9 M, Clappaert EJ, Cappellesso F, Caro AA, Gord\u00fan Peir\u00f3 A, Fredericq L, Hadadi E, Estap\u00e9 Senti M, Schiffelers R, van Grunsven LA, Aboubakar Nana F, De Geest BG, Deschoemaeker S, De Koker S, Lambolez F, Laoui D. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat Commun. 2024;15(1):10635.","journal-title":"Nat Commun"},{"issue":"11","key":"4562_CR8","doi-asserted-by":"publisher","first-page":"e2418306122","DOI":"10.1073\/pnas.2418306122","volume":"122","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Yu C, Chen Y, Luo W, Li M, Zou J, Xiao F, An S, Saiding Q, Tao W, Kong N, Xie T. Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and \u03b2-elemene combination therapy. Proc Natl Acad Sci U S A. 2025;122(11):e2418306122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"4562_CR9","doi-asserted-by":"publisher","first-page":"32689","DOI":"10.1021\/jacs.4c12166","volume":"146","author":"J Gan","year":"2024","unstructured":"Gan J, Lei J, Li Y, Lu M, Yu X, Yu G. Manganese oxide-incorporated hybrid lipid nanoparticles amplify the potency of mRNA vaccine via oxygen generation and STING activation. J Am Chem Soc. 2024;146(47):32689\u2013700.","journal-title":"J Am Chem Soc"},{"issue":"17","key":"4562_CR10","doi-asserted-by":"publisher","first-page":"e2410998","DOI":"10.1002\/adma.202410998","volume":"37","author":"X Guo","year":"2025","unstructured":"Guo X, Yang Z, Guo Z, Lai H, Meng H, Meng M, Li T, Li Z, Chen J, Feng Y, Pang X, Tian H, Chen X. A polymeric mRNA vaccine featuring enhanced site-specific mRNA delivery and inherent STING-stimulating performance for tumor immunotherapy. Adv Mater. 2025;37(17):e2410998.","journal-title":"Adv Mater"},{"issue":"24","key":"4562_CR11","doi-asserted-by":"publisher","first-page":"15499","DOI":"10.1021\/acsnano.4c00063","volume":"18","author":"B Wang","year":"2024","unstructured":"Wang B, Tang M, Chen Q, Ho W, Teng Y, Xiong X, Jia Z, Li X, Xu X, Zhang XQ. Delivery of mRNA encoding interleukin-12 and a stimulator of interferon genes agonist potentiates antitumor efficacy through reversing T cell exhaustion. ACS Nano. 2024;18(24):15499\u2013516.","journal-title":"ACS Nano"},{"key":"4562_CR12","doi-asserted-by":"publisher","first-page":"113756","DOI":"10.1016\/j.jconrel.2025.113756","volume":"383","author":"YA Kim","year":"2025","unstructured":"Kim YA, Jeong H, Kim H, Lee S, Kim KS, Na K. Lipid nanoparticles with prazole adjuvant to enhance the efficacy of mRNA cancer vaccines. J Control Release. 2025;383:113756.","journal-title":"J Control Release"},{"issue":"47","key":"4562_CR13","doi-asserted-by":"publisher","first-page":"32401","DOI":"10.1021\/acsnano.4c03518","volume":"18","author":"J Yoon","year":"2024","unstructured":"Yoon J, Fagan E, Jeong M, Park JH. In situ tumor-infiltrating lymphocyte therapy by local delivery of an mRNA encoding membrane-anchored anti-CD3 single-chain variable fragment. ACS Nano. 2024;18(47):32401\u201320.","journal-title":"ACS Nano"},{"issue":"22","key":"4562_CR14","doi-asserted-by":"publisher","first-page":"20672","DOI":"10.1021\/acsnano.5c01378","volume":"19","author":"K Cui","year":"2025","unstructured":"Cui K, Fangming Z, Shi T, Zhao S, Zhou Y, Liu X, Hu Y, Hu Z, Kong L, Zhang Z. Iterative screening of vitamin E-based functional lipid nanoparticles for mRNA delivery. ACS Nano. 2025;19(22):20672\u201392.","journal-title":"ACS Nano"},{"issue":"1","key":"4562_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","volume":"6","author":"I Lai","year":"2018","unstructured":"Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer. 2018;6(1):125.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4562_CR16","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med. 2022;28(11):2273\u201387.","journal-title":"Nat Med"},{"issue":"8","key":"4562_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23(8):526\u201343.","journal-title":"Nat Rev Cancer"},{"issue":"10432","key":"4562_CR18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403(10432):1192\u2013204.","journal-title":"Lancet"},{"key":"4562_CR19","doi-asserted-by":"publisher","unstructured":"Swetha K, Kotla NG, Tunki L, Jayaraj A, Bhargava SK, Hu H, Bonam SR, Kurapati R. Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. Vaccines (Basel). 2023;11(3). https:\/\/doi.org\/10.3390\/vaccines11030658","DOI":"10.3390\/vaccines11030658"},{"key":"4562_CR20","doi-asserted-by":"publisher","first-page":"115175","DOI":"10.1016\/j.addr.2023.115175","volume":"205","author":"P Sharma","year":"2024","unstructured":"Sharma P, Hoorn D, Aitha A, Breier D, Peer D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv Drug Deliv Rev. 2024;205:115175.","journal-title":"Adv Drug Deliv Rev"},{"key":"4562_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jconrel.2024.10.005","volume":"376","author":"X Li","year":"2024","unstructured":"Li X, Wu C, Li J, Yu J, Yang X, Yu L, Wang C, Kuai R. An immunostimulatory liponanogel reveals immune activation-enhanced drug delivery and therapeutic efficacy in cancer. J Control Release. 2024;376:167\u201383.","journal-title":"J Control Release"},{"issue":"8","key":"4562_CR22","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1021\/acsnano.4c14517","volume":"19","author":"Y Li","year":"2025","unstructured":"Li Y, Gan J, Lei J, Qi S, Yu X, Zhang W, Feng Y, Zhang Y, Cheng M, Ma L, Mao Z, Liu Z, Yu G. Catalytic hybrid lipid nanoparticles potentiate circle RNA-based cytokine immunotherapy. ACS Nano. 2025;19(8):7864\u201376.","journal-title":"ACS Nano"},{"issue":"3","key":"4562_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.4049\/jimmunol.1501399","volume":"198","author":"D Dominguez","year":"2017","unstructured":"Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang L, Zhang Z, Zhang Y, Fang D, Kuzel TM, Zhang B. Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 2017;198(3):1365\u201375.","journal-title":"J Immunol"},{"issue":"5","key":"4562_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ijc.32779","volume":"146","author":"L Qi","year":"2020","unstructured":"Qi L, Zhang Q, Miao Y, Kang W, Tian Z, Xu D, Xiao W, Fang F. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int J Cancer. 2020;146(5):1421\u201334.","journal-title":"Int J Cancer"},{"issue":"6","key":"4562_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s12276-024-01249-4","volume":"56","author":"MH Kang","year":"2024","unstructured":"Kang MH, Bae YS. IL-33 and IL-33-derived DC-based tumor immunotherapy. Exp Mol Med. 2024;56(6):1340\u20137.","journal-title":"Exp Mol Med"},{"issue":"7","key":"4562_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10529-020-02815-2","volume":"42","author":"L Xu","year":"2020","unstructured":"Xu L, Zheng Y, Wang J, Xu Y, Xie Y, Yang ZP. IL33 activates CD8\u2009+\u2009T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice. Biotechnol Lett. 2020;42(7):1113\u201321.","journal-title":"Biotechnol Lett"},{"key":"4562_CR27","doi-asserted-by":"publisher","first-page":"1455019","DOI":"10.3389\/fimmu.2024.1455019","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Hu L, Wang Y, Liu Q, Liu J, Long H, Li Q, Luo L, Peng Y. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. Front Immunol. 2024;15:1455019.","journal-title":"Front Immunol"},{"issue":"1","key":"4562_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, Yin J, Zhang W, Zhou H, Liu Z. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133.","journal-title":"Mol Cancer"},{"issue":"9","key":"4562_CR29","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1039\/D4BM01532K","volume":"13","author":"G Fu","year":"2025","unstructured":"Fu G, Zhao Y, Mao C, Liu Y. Enhancing nano-immunotherapy of cancer through cGAS-STING pathway modulation. Biomater Sci. 2025;13(9):2235\u201360.","journal-title":"Biomater Sci"},{"issue":"1","key":"4562_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):136.","journal-title":"Mol Cancer"},{"issue":"92","key":"4562_CR31","doi-asserted-by":"publisher","first-page":"eadj3945","DOI":"10.1126\/sciimmunol.adj3945","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Li S, Wang M, Wang X, Chen S, Sun Z, Ren X, Huang G, Sumer BD, Yan N, Fu YX, Gao J. STING licensing of type I dendritic cells potentiates antitumor immunity. Sci Immunol. 2024;9(92):eadj3945.","journal-title":"Sci Immunol"},{"key":"4562_CR32","doi-asserted-by":"publisher","first-page":"1579832","DOI":"10.3389\/fimmu.2025.1579832","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhu Y, Cao Y, Li Y, Zhang Z, Fleishman JS, Cheng S, Chen J, Ding M. The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers. Front Immunol. 2025;16:1579832.","journal-title":"Front Immunol"},{"key":"4562_CR33","first-page":"0102","volume":"6","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Li X, Qian F, Sun B, Wang X, Zhang Y, Zhang D, Geng M, Xie Z, Yang S. Fine-tuning bacterial cyclic di-AMP production for durable antitumor effects through the activation of the STING pathway. Res (Wash D C). 2023;6:0102.","journal-title":"Res (Wash D C)"},{"issue":"25","key":"4562_CR34","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.7150\/thno.37574","volume":"9","author":"T Su","year":"2019","unstructured":"Su T, Zhang Y, Valerie K, Wang XY, Lin S, Zhu G. STING activation in cancer immunotherapy. Theranostics. 2019;9(25):7759\u201371.","journal-title":"Theranostics"},{"key":"4562_CR35","doi-asserted-by":"publisher","first-page":"114573","DOI":"10.1016\/j.colsurfb.2025.114573","volume":"250","author":"H Zhang","year":"2025","unstructured":"Zhang H, Xu X, Li S, Huang H, Zhang K, Li W, Wang X, Yang J, Yin X, Qu C, Ni J, Dong X. Advances in nanoplatform-based multimodal combination therapy activating STING pathway for enhanced anti-tumor immunotherapy. Colloids Surf B Biointerfaces. 2025;250:114573.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"5","key":"4562_CR36","doi-asserted-by":"publisher","first-page":"054121","DOI":"10.1063\/1.4827598","volume":"7","author":"X Feng","year":"2013","unstructured":"Feng X, Ren Y, Jiang H. An effective splitting-and-recombination micromixer with self-rotated contact surface for wide Reynolds number range applications. Biomicrofluidics. 2013;7(5):054121.","journal-title":"Biomicrofluidics"},{"issue":"10","key":"4562_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/stem.3051","volume":"37","author":"I Kareva","year":"2019","unstructured":"Kareva I. Metabolism and gut microbiota in cancer immunoediting, CD8\/Treg ratios, immune cell homeostasis, and cancer (immuno)therapy: concise review. Stem Cells. 2019;37(10):1273\u201380.","journal-title":"Stem Cells"},{"issue":"3","key":"4562_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79(3):191.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"4562_CR39","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365\u201386.","journal-title":"Theranostics"},{"key":"4562_CR40","doi-asserted-by":"publisher","unstructured":"Pattu V, Krause E, Chang HF, Rettig J, Li X. IFN\u03b3 expression correlates with enhanced cytotoxicity in CD8\u2009+\u2009T cells. Int J Mol Sci. 2025;26(14). https:\/\/doi.org\/10.3390\/ijms26147024","DOI":"10.3390\/ijms26147024"},{"key":"4562_CR41","doi-asserted-by":"publisher","unstructured":"Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, McWhirter SM, Raulet DH. NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists. Sci Immunol. 2020;5(45). https:\/\/doi.org\/10.1126\/sciimmunol.aaz2738","DOI":"10.1126\/sciimmunol.aaz2738"},{"issue":"10","key":"4562_CR42","doi-asserted-by":"publisher","first-page":"e230034","DOI":"10.1148\/rg.230034","volume":"43","author":"BE Adrada","year":"2023","unstructured":"Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS. Triple-negative breast cancer: histopathologic features, genomics, and treatment. Radiographics. 2023;43(10):e230034.","journal-title":"Radiographics"},{"issue":"1","key":"4562_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22(1):145.","journal-title":"Mol Cancer"},{"key":"4562_CR44","doi-asserted-by":"publisher","first-page":"919072","DOI":"10.3389\/fonc.2022.919072","volume":"12","author":"C Luo","year":"2022","unstructured":"Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072.","journal-title":"Front Oncol"},{"issue":"38","key":"4562_CR45","doi-asserted-by":"publisher","first-page":"61069","DOI":"10.18632\/oncotarget.11179","volume":"7","author":"L Qin","year":"2016","unstructured":"Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, Fang D, Zhang Y, Kuzel TM, Zhang B. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016;7(38):61069\u201380.","journal-title":"Oncotarget"},{"issue":"2","key":"4562_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, Bhutkar A, Wittrup KD, Spranger S. Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity. Immunity. 2022;55(2):308\u2013e3239.","journal-title":"Immunity"},{"issue":"14","key":"4562_CR47","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","volume":"27","author":"Y Liang","year":"2021","unstructured":"Liang Y, Hannan R, Fu YX. Type I IFN activating type I dendritic cells for antitumor immunity. Clin Cancer Res. 2021;27(14):3818\u201324.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4562_CR48","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","volume":"184","author":"KC Lam","year":"2021","unstructured":"Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lop\u00e8s A, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184(21):5338\u2013e535621.","journal-title":"Cell"},{"issue":"1","key":"4562_CR49","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s41467-021-22033-2","volume":"12","author":"K Alicea-Torres","year":"2021","unstructured":"Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021;12(1):1717.","journal-title":"Nat Commun"},{"key":"4562_CR50","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.cbpa.2024.102499","volume":"81","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Wang ZM, Song D, Chen M, Xu Q. Rational design of lipid nanoparticles: overcoming physiological barriers for selective intracellular mRNA delivery. Curr Opin Chem Biol. 2024;81:102499.","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"4562_CR51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","volume":"34","author":"R Tenchov","year":"2023","unstructured":"Tenchov R, Sasso JM, Zhou QA. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug Chem. 2023;34(6):941\u201360.","journal-title":"Bioconjug Chem"},{"key":"4562_CR52","doi-asserted-by":"publisher","unstructured":"Hajiaghapour Asr M, Dayani F, Saedi Segherloo F, Kamedi A, O\u2019Neill A, MacLoughlin R, Doroudian M. Lipid nanoparticles as promising carriers for mRNA vaccines for viral lung infections. Pharmaceutics. 2023;15(4). https:\/\/doi.org\/10.3390\/pharmaceutics15041127","DOI":"10.3390\/pharmaceutics15041127"},{"key":"4562_CR53","doi-asserted-by":"publisher","unstructured":"Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, Tian Z, Hu Y, Zhao Y, Jiang S. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines (Basel). 2024;12(10). https:\/\/doi.org\/10.3390\/vaccines12101148","DOI":"10.3390\/vaccines12101148"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04562-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:02:16Z","timestamp":1783303336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04562-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4562"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04562-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"618"}}